e-Therapeutics plc Director/PDMR Shareholding (0295E)

TIDMETX

RNS Number : 0295E

e-Therapeutics plc

03 May 2017

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 3 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 2 May 2017 it granted 5,500,000 options over its ordinary shares of 0.1 pence each to Raymond Barlow, Chief Executive Officer of the Company, in accordance with the terms of Mr Barlow's employment contract. The options were granted under the e-Therapeutics Performance Share Plan in three tranches as follows:

2,000,000 share options with an exercise price of 16.76 pence per share (the "A Award");

1,750,000 share options with an exercise price of 20.95 pence per share (the "B Award"); and

1,750,000 share options with an exercise price of 25.14 pence per share (the "C Award")

of which 3,174,603 options were granted as Enterprise Management Incentive options, and the balance as unapproved options.

Following this grant, Raymond Barlow holds 5,500,000 options over ordinary shares in the Company (the "Options").

The Options vest on the first anniversary from the date of grant in respect of the A Award, on the second anniversary of the date of grant in respect of the B Award, and in equal monthly tranches over a three-year period from the date of grant in respect of the C Award. Vested Options may not be exercised prior to the second anniversary from the date of grant, but all vested Options remain exercisable up to and including the tenth anniversary of the date of grant, to the extent that the award performance targets applicable to the options have been met.

In the event of a change of control, if not already vested in full, the Options shall vest and become exercisable to the fullest extent possible.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ----------------------------------------------------------------- 
 a)   Name                      Raymond John Barlow 
---  ------------------------  --------------------------------------- 
 2    Reason for the notification 
---  ----------------------------------------------------------------- 
 a)   Position/status           Chief Executive Officer/Executive 
                                 Director 
---  ------------------------  --------------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  --------------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ----------------------------------------------------------------- 
 a)   Name                      e-Therapeutics plc 
---  ------------------------  --------------------------------------- 
 b)   LEI                       21380049RHSSJXWKYT18 
---  ------------------------  --------------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ----------------------------------------------------------------- 
 a)   Description of            Ordinary Shares of 0.1 pence 
       the financial 
       instrument, type          ISIN: GB00B2823H99 
       of instrument 
       Identification 
       code 
---  ------------------------  --------------------------------------- 
 b)   Nature of the             Grant of options to acquire shares 
       transaction 
---  ------------------------  --------------------------------------- 
 c)   Price(s) and              2,000,000 options to acquire ordinary 
       volume(s)                 shares at an exercise price of 
                                 16.76 pence per share; 
                                 1,750,000 options to acquire ordinary 
                                 shares at an exercise price of 
                                 20.95 pence per share; and 
 
                                 1,750,000 options to acquire ordinary 
                                 shares at an exercise price of 
                                 25.14 pence per share 
---  ------------------------  --------------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  --------------------------------------- 
 e)   Date of the transaction   2 May 2017 
---  ------------------------  --------------------------------------- 
 f)   Place of the              Outside a trading venue 
       transaction 
---  ------------------------  --------------------------------------- 
 

For further information, please contact:

Contacts:

 
 e-Therapeutics plc          Tel: [phone] 
  Iain Ross, Chairman         883 125 
  Steve Medlicott, Finance    www.etherapeutics.co.uk 
  Director 
 Numis Securities Limited    Tel: +44 (0) 207 
  Michael Meade / Freddie     260 1000 
  Barnfield                   www.numis.com 
  (Corporate Finance) 
  James Black (Corporate 
  Broking) 
 Instinctif Partners         Tel: +44 (0) 207 
  Melanie Toyne Sewell /      457 2020 
  Alex Shaw                   Email: [e-mail] 
 

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLIFEDEFIVIID

(END) Dow Jones Newswires

May 03, 2017 04:00 ET (08:00 GMT)